
3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH Yahoo Finance
SAN MATEO, Calif. and HANGZHOU and SHAOXING, China, May 1, 2019 /PRNewswire/ — 3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc.
